Heteroplasmy at the single mitochondrion level
单线粒体水平的异质性
基本信息
- 批准号:7025013
- 负责人:
- 金额:$ 10.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-04-01 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The immediate goal of the applicant is to devote 75% of his time during the five-year support period of this K02 award to the exploration of novel approaches to subcellular biology. The time off from teaching and service provided by the award would allow him to focus more intensely on the development of new strategies based on individual organelle analysis that would then be used to better understand disease and aging. These strategies are being developed as part of two ongoing R01 projects in his laboratory that investigate (i) the role of mitochondrial DNA (mtDNA) mutations in aging and age-related diseases, and (ii) subcellular drug metabolism. This award would also allow the candidate to devote more time to (i) integrating robotics, cybrid technology, and proteomics expertise into his laboratory; (ii) training scientists, (iii) establishing a solid network of collaborations, and (iv) providing cohesive leadership to a multi-disciplinary research team. In the research plan of this application, the candidate proposes to study the distributions of mtDNA mutations based on individual mitochondrion measurements. While the accumulation of these mutations has been implicated in the aging process and age-related diseases, the link between mutation levels and age-related phenotypes or disease symptoms is not known. The hypothesis of this application is that individual mitochondria contain both wild-type and mutated DNA, a condition known as heteroplasmy, which determines how mutations are distributed and propagated. Two models will be used to test this hypothesis: cybrid cell lines harboring large mtDNA deletions, and skeletal muscle tissue from aged Fisher 344 rats that is expected to have accumulated similar deletions with age. The three goals of the study are: (i) establish the existence of heteroplasmy within individual mitochondria, (ii) monitor changes in heteroplasmy following cybrid fusion, and (iii) measure heteroplasmy along skeletal muscle fibers. Since no technology exists to directly test this hypothesis, this application will require the further development of the applicant's strategies initially on based capillary electrophoresis with laser-induced fluorescence detection for characterizing mtDNA and peptide expression in individual organelles. Upon the completion of this K02 award, the applicant is expected to have provided the scientific community with new technologies and to be directing a widely recognized research program.
描述(由申请人提供):申请人的近期目标是在K 02奖的五年支持期内,将75%的时间用于探索亚细胞生物学的新方法。该奖项提供的教学和服务时间将使他能够更专注于基于个体细胞器分析的新策略的开发,然后用于更好地了解疾病和衰老。这些策略是作为他实验室正在进行的两个R 01项目的一部分而开发的,该项目研究(i)线粒体DNA(mtDNA)突变在衰老和年龄相关疾病中的作用,以及(ii)亚细胞药物代谢。该奖项还将使候选人能够投入更多的时间(i)将机器人技术,cybrid技术和蛋白质组学专业知识整合到他的实验室中;(ii)培训科学家,(iii)建立稳固的合作网络,以及(iv)为多学科研究团队提供凝聚力的领导。在本次申请的研究计划中,候选人提出基于个体的线粒体测量来研究mtDNA突变的分布。虽然这些突变的积累与衰老过程和年龄相关疾病有关,但突变水平与年龄相关表型或疾病症状之间的联系尚不清楚。该应用的假设是,单个线粒体包含野生型和突变的DNA,这种情况称为异质性,它决定了突变如何分布和传播。将使用两种模型来检验这一假设:携带大的mtDNA缺失的胞质杂交细胞系,以及来自老年Fisher 344大鼠的骨骼肌组织,预计随着年龄的增长会积累类似的缺失。该研究的三个目标是:(i)确定个体线粒体内异质性的存在,(ii)监测胞质融合后异质性的变化,以及(iii)测量沿着骨骼肌纤维的异质性。由于不存在直接测试该假设的技术,因此本申请将需要进一步开发申请人的策略,该策略最初基于毛细管电泳与激光诱导荧光检测,用于表征单个细胞器中的mtDNA和肽表达。在完成K 02奖项后,申请人有望为科学界提供新技术,并指导一项广泛认可的研究计划。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDGAR A ARRIAGA其他文献
EDGAR A ARRIAGA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDGAR A ARRIAGA', 18)}}的其他基金
Subcellular Analysis of Caenohabdibtis elegans Aging Models
秀丽隐杆线虫衰老模型的亚细胞分析
- 批准号:
8457310 - 财政年份:2013
- 资助金额:
$ 10.81万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 10.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 10.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 10.81万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 10.81万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 10.81万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 10.81万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 10.81万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 10.81万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 10.81万 - 项目类别:
Studentship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 10.81万 - 项目类别: